Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical reports news on its global medical-device business in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate-site and home-care settings. Company updates commonly cover quarterly results, fiscal guidance, GAAP and non-GAAP profitability measures, and revenue trends across the Consumables, Infusion Systems and Vital Care product lines.
Recurring announcements also include earnings-call schedules, investor conference participation and business changes that affect reported comparisons, including the completed divestiture of the IV Solutions business. The company’s news flow centers on product-line performance, margin trends, adjusted EBITDA, adjusted diluted earnings per share and management commentary on operating results.
ICU Medical (Nasdaq:ICUI) reported its Q2 2025 financial results with revenue of $548.9 million, down from $596.5 million in Q2 2024. The company showed improved profitability with GAAP net income of $35.3 million ($1.43 per diluted share), compared to a net loss of $(21.4) million in Q2 2024.
Key metrics include improved GAAP gross margin of 38% (up from 35%), adjusted diluted EPS of $2.10 (up from $1.56), and adjusted EBITDA of $100.3 million (up from $91.3 million). The company updated its FY2025 guidance, narrowing adjusted EBITDA expectations to $380-390 million and adjusted EPS to $6.85-7.15.
ICU Medical (Nasdaq: ICUI), a leading medical products manufacturer, has scheduled its second quarter 2025 earnings release and conference call. The company will release Q2 2025 results on Thursday, August 7, 2025, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET.
Investors can access the call via phone at (800) 267-6316 using conference ID "ICUMED" or through a webcast available on the company's website. The webcast will also be available for replay through ICU Medical's investor relations section at www.icumed.com.
ICU Medical (NASDAQ:ICUI) reported its Q1 2025 financial results, showing revenue growth to $604.7 million, up from $566.7 million in Q1 2024. The company's GAAP gross profit increased to $210.1 million with a gross margin of 35%, compared to $185.2 million and 33% in the prior year.
While still reporting a GAAP net loss of $(15.5) million, or $(0.63) per diluted share, this represents an improvement from the $(39.5) million loss in Q1 2024. Adjusted diluted EPS rose to $1.72 from $0.96, and adjusted EBITDA increased to $99.4 million from $78.8 million year-over-year.
By product line, Consumables generated $266.2 million (+$22.1M YoY), Infusion Systems reached $166.3 million (+$9.0M YoY), and Vital Care contributed $172.2 million (+$6.9M YoY), including $5.2 million from Pfizer contract manufacturing.
ICU Medical (NASDAQ: ICUI) and Otsuka Pharmaceutical Factory (OPF) have completed the formation of Otsuka ICU Medical LLC, a joint venture aimed at strengthening IV solutions manufacturing and innovation in North America. The partnership creates one of the largest global IV solutions manufacturing networks with combined production of 1.4 billion annual units.
The joint venture combines OPF's expertise and global manufacturing scale across 16 IV solutions production sites in Asia with ICU Medical's North American production facility in Austin, Texas. The collaboration will enhance supply chain resiliency and introduce new PVC-free technologies to the North American market. ICU Medical will provide commercial services for seamless operations.
ICU Medical (NASDAQ: ICUI) has scheduled its first quarter 2025 earnings release and conference call for Thursday, May 8, 2025. The company will release its Q1 2025 results at approximately 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET.
Investors can access the call via phone at (800) 225-9448 using conference ID 'ICUMED'. Additionally, a simultaneous webcast will be available through the Investors section of the company's website at www.icumed.com, with replay options available.
ICU Medical (NASDAQ:ICUI) has received FDA 510(k) clearance for its new Plum Solo™ and updated Plum Duo™ precision IV pumps, along with LifeShield™ infusion safety software. These devices introduce a new category of precision IV pumps designed to address delivery variability with ±3% accuracy in real-world conditions.
The single-channel Plum Solo complements the dual-channel Plum Duo, offering healthcare systems flexibility in device configuration. Both pumps feature compatibility with whole blood and blood products, and include advanced features such as full-color touchscreens, simplified drug library management, and IV-EHR interoperability.
This milestone marks ICU Medical's achievement of 5 FDA 510(k) clearances in the past 18 months, with plans to expand their LifeShield platform with next-generation Medfusion™ syringe pump and CADD™ pain and ambulatory pump products.
ICU Medical (Nasdaq:ICUI), a leading medical products innovator, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference, scheduled for April 7-10, 2025.
The company's presentation is set for Monday, April 7, 2025, at 8:00 a.m. PT (11:00 a.m. ET). Management will also engage in one-on-one meetings throughout the day. Investors and interested parties can access the live webcast through the company's website at icumed.com under the Investors tab and Event Calendar section. A replay option will be available for those unable to attend the live presentation.
ICU Medical (Nasdaq:ICUI), a leading medical products innovator, has announced its participation in the upcoming KeyBanc Healthcare Forum, scheduled for March 18-19, 2025. The company will engage in a fireside chat on March 19, 2025, at 8:15 a.m. PT (11:15 a.m. ET).
The event will be held virtually, and company management will also conduct one-on-one meetings throughout the day. Investors and interested parties can access the live webcast through ICU Medical's website at icumed.com under the Investors tab and Event Calendar section. A replay option will be available for those unable to attend the live session.
ICU Medical (NASDAQ:ICUI) reported Q4 2024 financial results with revenue of $629.8 million, up from $587.9 million in Q4 2023. The company's GAAP gross profit increased to $227.3 million with a margin of 36.1%, compared to $171.6 million and 29.2% in the prior year.
Despite revenue growth, ICUI posted a GAAP net loss of $(23.8) million, or $(0.97) per diluted share, wider than the $(17.1) million loss in Q4 2023. However, adjusted metrics showed improvement with adjusted EPS of $2.11 and adjusted EBITDA of $105.5 million, up from $1.57 and $86.3 million respectively.
For fiscal year 2025, ICUI projects GAAP net loss between $(45) million to $(28) million, with adjusted EBITDA guidance of $395-425 million and adjusted EPS of $6.55-7.25. The company's planned IV Solutions joint venture, expected to close in Q2 2025, could reduce 2025 adjusted EBITDA by $15-20 million while remaining neutral to adjusted EPS.
ICU Medical (Nasdaq: ICUI) has announced its schedule for the fourth quarter 2024 earnings release and conference call. The company will release Q4 2024 results on Thursday, February 27, 2025, at approximately 4:00 p.m. ET (1:00 p.m. PT), followed by a conference call at 4:30 p.m. ET (1:30 p.m. PT) on the same day.
Investors can access the call via telephone at (800) 445-7795 using conference ID 'ICUMED'. Additionally, a webcast will be available through the Investors tab on ICU Medical's website at www.icumed.com, with replay options available.